PriceSensitive

Polynovo (ASX:PNV) appoints Joshua Cheetam as Director of Research and Development

Health Care
ASX:PNV      MCAP $1.442B
09 May 2021 16:00 (AEST)

PolyNovo (PNV) has appointed Dr Joshua Cheetam as Director of Research and Development.

Joshua has over 25 years of experience in research and development, commercialisation of medical products and manufacturing operations.

Previously, he has worked as product development manager, operations director, research and development director and Chief Technology Officer at SDI, a medical devices company that specialises in manufacturing dental materials.

Joshua will focus on quickly growing a research and development team to
capture and commercialise the many business developments and new product opportunities.

His role is to lead the innovation strategy and research and development activities and to develop the future product portfolio for PolyNovo.

“This is a very exciting and significant appointment that will spearhead the
building of a world-class research and development team befitting the company’s market capitalisation,” Chairman David Williams said.

Managing Director Paul Brennan says the company will continue to invest in the expansion of its research and development team.

“Joshua will be recruiting additional scientists to bolster the team and accelerate our pipeline of new products,” he added.

On the market close for the weekend, Polynovo is down 2.46 per cent, trading at $2.78 per share.

Related News